Chugai and UCSF Establish Master Collaboration Agreement for Drug Discovery Research
核心洞察
Chugai Pharmaceutical and UCSF have entered into a multi-year Master Collaboration Agreement to advance drug discovery research in disease biology, novel drug targets, and new therapeutic approaches.
The partnership will combine UCSF's translational research capabilities with Chugai's proprietary antibody engineering, SnipeTide™ macrocyclic peptide, and small molecule platforms.
An initial research project is already underway with a UCSF principal investigator, signaling immediate momentum under the new framework.
Chugai Pharmaceutical Co., Ltd. and the University of California, San Francisco (UCSF) (搜索) have entered into a Master Collaboration Agreement aimed at accelerating drug discovery research, the organizations announced on August 6/7, 2026. The multi-year agreement establishes a framework to facilitate research collaborations spanning the exploration of disease biology, the identification of novel drug targets, and the development of new therapeutic approaches. An initial research project is already underway with a UCSF principal investigator.
The agreement represents a significant step in Chugai's global open innovation strategy, deepening the company's ties with one of the world's leading academic research institutions. Under the framework, the two organizations will leverage UCSF's scientific innovation and translational research capabilities together with Chugai's proprietary technologies—including antibody engineering, macrocyclic peptides via the SnipeTide™ platform, and small molecules—to advance early-stage research toward next-generation medicines.
"This Master Collaboration Agreement reflects Chugai's commitment to open innovation and represents an important opportunity to advance research collaborations with UCSF," said Norihisa Onozawa, Executive Vice President at Chugai. "We believe this agreement will create new opportunities to translate innovative science into potential medicines by bringing together complementary capabilities from both organizations. We hope the research conducted under this agreement will help bring innovative medicines to patients as quickly as possible."
A Bridge Between Two Innovation Hubs
The agreement was developed through close collaboration between Chugai Partnering U.S., the partnering function based at the South San Francisco branch of Chugai Pharma USA, Inc. (CPUSA), a wholly owned subsidiary of Chugai, and UCSF Innovation Ventures, UCSF's office responsible for industry partnerships, technology commercialization, and innovation initiatives.
The South San Francisco office, launched approximately six months prior to this announcement, is led by Andrew Wong, Head of Chugai Partnering, U.S. The team works closely with Chugai's global partnering teams worldwide to connect with biotech startups, academic researchers, and venture investors. "Our mission is to identify and build partnerships with the most innovative academic researchers, biotechnology companies, and venture investors in the U.S.," Wong stated in a recent interview describing the office's strategic role.
Complementary Capabilities and Strategic Fit
David Morris, MD, Vice Chancellor for Business Development, Innovation and Partnerships at UCSF, emphasized the catalytic role of such industry-academic partnerships. "Innovation Ventures acts as a catalyst for turning early UCSF science into real therapies, and partners like Chugai Pharmaceutical offer complementary technologies that can turbocharge that environment even further," Morris said. "This agreement gives us a much faster, more direct way to bring UCSF's science together with Chugai's discovery capabilities and development expertise."
The collaboration aligns with Chugai's broader partnering philosophy, which emphasizes scientific synergy over transactional speed. Yutaka Matsuda, Global Head of Search & Evaluation at Chugai in Tokyo, described the company's approach: "Our style is unique compared with that of other large pharmaceutical companies. Our research division has a strong voice because we focus on creating synergy with its activities. Our goal is not simply to speed up the contracting process, but to pursue high-quality scientific outcomes with our partners."
Chugai's Expanding U.S. Presence
The UCSF agreement comes amid a broader expansion of Chugai's footprint in the Bay Area life sciences ecosystem. In May 2026, Chugai joined the Industry Affiliate Program at Bakar Bio Labs, UC Berkeley's flagship incubator for biotech startups. As an Industry Affiliate, Chugai engages closely with resident startup teams and contributes to scientific and ecosystem development initiatives.
As a member of the Roche Group, Chugai operates with its own R&D and partnering strategy, a model that Wong describes as having "the best of both worlds." The company's track record includes a bispecific antibody for hemophilia (搜索), discovered and developed by Chugai and later commercialized globally through the Roche Group—a model the team believes can be replicated with external partners.
For UCSF and Chugai alike, the Master Collaboration Agreement signals a shared commitment to translating innovative academic science into therapies that can reach patients globally, with the framework designed to streamline and accelerate that translational journey.